{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:28:08Z","timestamp":1792096088211,"version":"4.4.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012306","name":"Universit\u00e0 degli Studi di Trieste","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012306","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This joint Position Paper, developed by the Italian Expert Panel on Alzheimer convened by the Italian Society of Neurology with participation from multiple scientific societies, outlines strategic guidelines for reorganizing the patient journey in the era of anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease. Emphasizing a multidisciplinary and integrated approach, the document recommends a patient journey that begins with early identification of cognitive impairment by General Practitioners, continues with specialized assessments at Memory and Dementia Centres, and leads, in carefully selected cases, to initiation of anti-amyloid monoclonal antibody therapy. It advocates the rational use of diagnostic tools, including plasma and cerebrospinal fluid biomarkers, advanced neuroimaging (MRI and PET), and genetic profiling (\n                    <jats:italic>ApoE<\/jats:italic>\n                    genotyping), not only to identify eligible patients but also to stratify those requiring alternative care strategies. The paper further defines minimum requirements for the accreditation of prescribing and infusion centres, highlighting the clinical competencies, structural resources, and inter-professional communication protocols necessary to ensure safety and appropriateness. Recognizing both the therapeutic potential and the organizational challenges associated with anti-amyloid monoclonal antibodies, the document aims to guide healthcare policymakers, institutions, and practitioners toward a coordinated reorganization of the diagnostic-therapeutic pathway, ensuring the safe and effective use of these treatments and ultimately improving outcomes and quality of care for individuals with Alzheimer\u2019s disease.\n                  <\/jats:p>","DOI":"10.1007\/s10072-025-08576-y","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T02:47:30Z","timestamp":1760669250000},"page":"6875-6894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8703-6940","authenticated-orcid":false,"given":"Alberto","family":"Benussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Rosa","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bellelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bozzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Brignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Cagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Francesca","family":"Calloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirio","family":"Cocozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Cosottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Falini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gaetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Gotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Logroscino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Marcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Marrocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Mecocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Mossello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Palleschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Pantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tessitore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"8576_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG et al (2021) Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis 8:398\u2013410. https:\/\/doi.org\/10.14283\/jpad.2021.41","journal-title":"J Prev Alzheimers Dis"},{"key":"8576_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10:362\u2013377","journal-title":"J Prev Alzheimers Dis"},{"key":"8576_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Selkoe DJ, Schindler SE (2025) Donanemab: appropriate use recommendations. J Prev Alzheimers Dis 12:100150. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150","journal-title":"J Prev Alzheimers Dis"},{"key":"8576_CR4","doi-asserted-by":"publisher","unstructured":"Jeon SY, Wang SM, Roh HW et al (2025) Practical guide of the Korean Association for Geriatric Psychiatry to anti-amyloid monoclonal antibody therapy for Alzheimer\u2019s disease: focused on lecanemab. J Korean Med Sci 40. https:\/\/doi.org\/10.3346\/jkms.2025.40.e215","DOI":"10.3346\/jkms.2025.40.e215"},{"key":"8576_CR5","doi-asserted-by":"publisher","unstructured":"Felbecker A, Rouaud O, Lathuilliere A et al (2025) Anti-amyloid monoclonal antibodies for the treatment of Alzheimer disease: intersocietal recommendations for their appropriate use in Switzerland. Neurodegener Dis:1\u201320. https:\/\/doi.org\/10.1159\/000545799","DOI":"10.1159\/000545799"},{"key":"8576_CR6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.14283\/jpad.2024.153","volume":"11","author":"F Jessen","year":"2024","unstructured":"Jessen F, Kramberger MG, Angioni D (2024) Progress in the treatment of Alzheimer\u2019s disease is needed \u2013 position statement of European Alzheimer\u2019s Disease Consortium (EADC) investigators. J Prev Alzheimers Dis 11:1212\u20131218","journal-title":"J Prev Alzheimers Dis"},{"key":"8576_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100094","volume":"12","author":"N Villain","year":"2025","unstructured":"Villain N, Planche V, Lilamand M et al (2025) Lecanemab for early Alzheimer\u2019s disease: appropriate use recommendations from the French federation of memory clinics. J Prev Alzheimers Dis 12:100094","journal-title":"J Prev Alzheimers Dis"},{"key":"8576_CR8","unstructured":"Istituto Superiore di Sanit\u00e0 (2024) National guideline - diagnosis and treatment of dementia and mild cognitive impairment. https:\/\/www.iss.it\/documents\/d\/guest\/the-full-guideline-english-version. Accessed 19 Aug 2025"},{"key":"8576_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jalz.2016.09.009","volume":"13","author":"SK Herukka","year":"2017","unstructured":"Herukka SK, Simonsen AH, Andreasen N (2017) Recommendations for cerebrospinal fluid Alzheimer\u2019s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement 13:285\u2013295","journal-title":"Alzheimers Dement"},{"issue":"3","key":"8576_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1474-4422(23)00447-7","volume":"23","author":"GB Frisoni","year":"2024","unstructured":"Frisoni GB, Festari C, Massa F et al (2024) European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol 23(3):302\u2013312","journal-title":"Lancet Neurol"},{"key":"8576_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB et al (2021) Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol 20:484\u2013496","journal-title":"Lancet Neurol"},{"key":"8576_CR12","doi-asserted-by":"publisher","unstructured":"Dubois B, Villain N, Schneider L et al (2024) Alzheimer disease as a clinical-biological construct-an International Working Group recommendation. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3770","DOI":"10.1001\/jamaneurol.2024.3770"},{"key":"8576_CR13","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20:5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"key":"8576_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14338","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J et al (2025) Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.14338","journal-title":"Alzheimers Dement"},{"key":"8576_CR15","unstructured":"Ministero della Salute (2022) DECRETO 23 maggio 2022, n. 77 - Regolamento recante la definizione di modelli e standard per lo sviluppo dell\u2019assistenza territoriale nel Servizio sanitario nazionale. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2022\/06\/22\/22G00085\/SG. Accessed 19 Aug 2025"},{"key":"8576_CR16","unstructured":"Presidenza del Consiglio dei ministri conferenza unificata (2014) Piano nazionale demenze - Strategie per la promozione ed il miglioramento della qualit\u00e0 e dell\u2019appropriatezza degli interventi assistenziali nel settore delle demenze. https:\/\/www.gazzettaufficiale.it\/atto\/stampa\/serie_generale\/originario. Accessed 23 Aug 2025"},{"key":"8576_CR17","doi-asserted-by":"publisher","unstructured":"Marra C, Beccia F, Caffarra P et al (2025) Towards a new value-based scenario for the management of dementia in Italy: a SINdem delphi consensus study. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-025-08143-5","DOI":"10.1007\/s10072-025-08143-5"},{"key":"8576_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-2-1","volume":"2","author":"AB Mitnitski","year":"2002","unstructured":"Mitnitski AB, Graham JE, Mogilner AJ, Rockwood K (2002) Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatr 2:1. https:\/\/doi.org\/10.1186\/1471-2318-2-1","journal-title":"BMC Geriatr"},{"key":"8576_CR19","doi-asserted-by":"crossref","unstructured":"Clegg A, Young J, Iliffe S et al (2013) Frailty in elderly people. Lancet. Elsevier B.V.:752\u2013762","DOI":"10.1016\/S0140-6736(12)62167-9"},{"key":"8576_CR20","doi-asserted-by":"publisher","unstructured":"Vetrano DL, Zucchelli A, Onder G et al (2023) Frailty detection among primary care older patients through the Primary Care Frailty Index (PC-FI). Sci Rep 13. https:\/\/doi.org\/10.1038\/s41598-023-30350-3","DOI":"10.1038\/s41598-023-30350-3"},{"key":"8576_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/afw039","volume":"45","author":"A Clegg","year":"2016","unstructured":"Clegg A, Bates C, Young J (2016) Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing 45:353\u2013360. https:\/\/doi.org\/10.1093\/ageing\/afw039","journal-title":"Age Ageing"},{"key":"8576_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1046\/j.1532-5415.2002.50122.x","volume":"50","author":"H Brodaty","year":"2002","unstructured":"Brodaty H, Pond D, Kemp NM et al (2002) The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc 50:530\u2013534. https:\/\/doi.org\/10.1046\/j.1532-5415.2002.50122.x","journal-title":"J Am Geriatr Soc"},{"key":"8576_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1017\/S104161020999113X","volume":"22","author":"A Pirani","year":"2010","unstructured":"Pirani A, Brodaty H, Martini E (2010) The validation of the Italian version of the GPCOG (GPCOG-It): a contribution to cross-national implementation of a screening test for dementia in general practice. Int Psychogeriatr 22:82\u201390. https:\/\/doi.org\/10.1017\/S104161020999113X","journal-title":"Int Psychogeriatr"},{"key":"8576_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jad.2020.09.131","volume":"279","author":"L Costantini","year":"2021","unstructured":"Costantini L, Pasquarella C, Odone A et al (2021) Screening for depression in primary care with patient health questionnaire-9 (PHQ-9): a systematic review. J Affect Disord 279:473\u2013483","journal-title":"J Affect Disord"},{"key":"8576_CR25","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1001\/jama.2020.6504","volume":"323","author":"B Levis","year":"2020","unstructured":"Levis B, Sun Y, He C (2020) Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis. JAMA 323:2290\u20132300","journal-title":"JAMA"},{"key":"8576_CR26","volume-title":"Depressione dell\u2019anziano nell\u2019ambulatorio del medico di medicina generale: dai sintomi alla terapia","author":"G Biggio","year":"2017","unstructured":"Biggio G, Brignoli O, Bruni AC et al (2017) Depressione dell\u2019anziano nell\u2019ambulatorio del medico di medicina generale: dai sintomi alla terapia. SIMG Supplemento"},{"key":"8576_CR27","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1007\/s10072-023-06885-8","volume":"44","author":"G Bellelli","year":"2023","unstructured":"Bellelli G, Zucchelli A, Benussi A (2023) Assessing frailty at the centers for dementia and cognitive decline in Italy: potential implications for improving care of older people living with dementia. Neurol Sci 44:3509\u20133514. https:\/\/doi.org\/10.1007\/s10072-023-06885-8","journal-title":"Neurol Sci"},{"key":"8576_CR28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4088\/JCP.tk16043ah5c","volume":"78","author":"L Culpepper","year":"2017","unstructured":"Culpepper L, Lam RW, McIntyre RS (2017) Cognitive impairment in patients with depression: awareness, assessment, and management. J Clin Psychiatry 78:1383\u20131394","journal-title":"J Clin Psychiatry"},{"key":"8576_CR29","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","volume":"7","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos CG, Carrillo MC, Ryan JM (2011) Neuropsychiatric symptoms in Alzheimer\u2019s disease. Alzheimers Dement 7:532\u2013539","journal-title":"Alzheimers Dement"},{"key":"8576_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jagp.2024.08.015","volume":"33","author":"JC Nelson","year":"2025","unstructured":"Nelson JC, Gandelman JA, Mackin RS (2025) A systematic review of antidepressants and psychotherapy commonly used in the treatment of late life depression for their effects on cognition. Am J Geriatr Psychiatry 33:287\u2013304. https:\/\/doi.org\/10.1016\/j.jagp.2024.08.015","journal-title":"Am J Geriatr Psychiatry"},{"key":"8576_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-221272","volume":"95","author":"R Olmos-Villase\u00f1or","year":"2023","unstructured":"Olmos-Villase\u00f1or R, Sepulveda-Silva C, Julio-Ramos T (2023) Phonological and semantic fluency in Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis 95:1\u201312","journal-title":"J Alzheimers Dis"},{"key":"8576_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3233\/JAD-230921","volume":"98","author":"F Rapos Pereira","year":"2024","unstructured":"Rapos Pereira F, George N, Dalla Barba G et al (2024) The memory binding test detects early subtle episodic memory decline in preclinical Alzheimer\u2019s disease: a longitudinal study. J Alzheimers Dis 98:465\u2013479. https:\/\/doi.org\/10.3233\/JAD-230921","journal-title":"J Alzheimers Dis"},{"key":"8576_CR33","doi-asserted-by":"publisher","unstructured":"Conca F, Esposito V, Rundo F et al (2022) Italian adaptation of the uniform data set neuropsychological test battery (I-UDSNB 1.0): development and normative data. Alzheimer's Res Ther 14. https:\/\/doi.org\/10.1186\/s13195-022-01056-x","DOI":"10.1186\/s13195-022-01056-x"},{"key":"8576_CR34","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s40520-022-02089-w","volume":"34","author":"EN Aiello","year":"2022","unstructured":"Aiello EN, Pasotti F, Appollonio I, Bolognini N (2022) Equating Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores: conversion norms from a healthy Italian population sample. Aging Clin Exp Res 34:1721\u20131724. https:\/\/doi.org\/10.1007\/s40520-022-02089-w","journal-title":"Aging Clin Exp Res"},{"key":"8576_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"8576_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"8576_CR37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/23279095.2021.1952588","volume":"30","author":"Y Wu","year":"2023","unstructured":"Wu Y, Zhang Y, Yuan X et al (2023) Influence of education level on MMSE and MoCA scores of elderly inpatients. Applied Neuropsychology: Adult 30:414\u2013418. https:\/\/doi.org\/10.1080\/23279095.2021.1952588","journal-title":"Applied Neuropsychology: Adult"},{"key":"8576_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/09084282.2011.643962","volume":"19","author":"NS Vigliecca","year":"2012","unstructured":"Vigliecca NS, Pe\u00f1alva MC, Molina SC et al (2012) Is the Folstein\u2019s mini-mental test an aphasia test? Appl Neuropsychol Adult 19:221\u2013228. https:\/\/doi.org\/10.1080\/09084282.2011.643962","journal-title":"Appl Neuropsychol Adult"},{"key":"8576_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179\u2013186","journal-title":"Gerontologist"},{"issue":"Suppl 1","key":"8576_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1017\/S1041610297004870","volume":"9","author":"JC Morris","year":"1997","unstructured":"Morris JC (1997) Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9(Suppl 1):173\u2013176; discussion 177-8. https:\/\/doi.org\/10.1017\/S1041610297004870","journal-title":"Int Psychogeriatr"},{"key":"8576_CR41","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412\u20132414. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a","journal-title":"Neurology"},{"key":"8576_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/pcn.12463","volume":"71","author":"GM MacQueen","year":"2017","unstructured":"MacQueen GM, Memedovich KA (2017) Cognitive dysfunction in major depression and bipolar disorder: assessment and treatment options. Psychiatry Clin Neurosci 71:18\u201327","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"8576_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jalz.2015.05.017","volume":"12","author":"Z Ismail","year":"2016","unstructured":"Ismail Z, Smith EE, Geda Y (2016) Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 12(2):195\u2013202. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.017","journal-title":"Alzheimers Dement"},{"key":"8576_CR44","doi-asserted-by":"crossref","unstructured":"Ickowicz E (2012) Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society expert panel on the care of older adults with multimorbidity. J Am Geriatr Soc 60","DOI":"10.1111\/j.1532-5415.2012.04188.x"},{"key":"8576_CR45","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1038\/s41380-025-03021-0","volume":"30","author":"D Mengel","year":"2025","unstructured":"Mengel D, Soter E, Ott JM et al (2025) Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer\u00b4s disease. Mol Psychiatry 30:3150\u20133159. https:\/\/doi.org\/10.1038\/s41380-025-03021-0","journal-title":"Mol Psychiatry"},{"key":"8576_CR46","doi-asserted-by":"publisher","unstructured":"Giacomucci G, Mazzeo S, Crucitti C et al (2023) Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer\u2019s Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment. J Neurol Sci 453. https:\/\/doi.org\/10.1016\/j.jns.2023.120805","DOI":"10.1016\/j.jns.2023.120805"},{"key":"8576_CR47","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","volume":"269","author":"G Giacomucci","year":"2022","unstructured":"Giacomucci G, Mazzeo S, Bagnoli S et al (2022) Plasma neurofilament light chain as a biomarker of Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment. J Neurol 269:4270\u20134280. https:\/\/doi.org\/10.1007\/s00415-022-11055-5","journal-title":"J Neurol"},{"key":"8576_CR48","doi-asserted-by":"crossref","unstructured":"Frisoni GB, Altomare D, Ribaldi F et al (2023) Dementia prevention in memory clinics: recommendations from the European task force for brain health services. Lancet Reg Health Europe 26","DOI":"10.1016\/j.lanepe.2022.100576"},{"key":"8576_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY et al (2024) Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404:572\u2013628","journal-title":"Lancet"},{"key":"8576_CR50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","volume":"46","author":"PM Cogswell","year":"2025","unstructured":"Cogswell PM, Andrews TJ, Barakos JA et al (2025) Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities. Am J Neuroradiol 46:24\u201332. https:\/\/doi.org\/10.3174\/ajnr.A8469","journal-title":"Am J Neuroradiol"},{"key":"8576_CR51","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.3174\/ajnr.A7586","volume":"43","author":"PM Cogswell","year":"2022","unstructured":"Cogswell PM, Barakos JA, Barkhof F (2022) Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. Am J Neuroradiol 43:E19\u2013E35. https:\/\/doi.org\/10.3174\/ajnr.A7586","journal-title":"Am J Neuroradiol"},{"key":"8576_CR52","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M et al (2023) Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146:4414\u20134424","journal-title":"Brain"},{"key":"8576_CR53","doi-asserted-by":"publisher","unstructured":"Honig LS, Sabbagh MN, van Dyck CH et al (2024) Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimer's Res Ther 16. https:\/\/doi.org\/10.1186\/s13195-024-01441-8","DOI":"10.1186\/s13195-024-01441-8"},{"key":"8576_CR54","doi-asserted-by":"publisher","unstructured":"Zimmer JA, Ardayfio P, Wang H et al (2025) Amyloid-related imaging abnormalities with donanemab in Early Symptomatic Alzheimer Disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0065","DOI":"10.1001\/jamaneurol.2025.0065"},{"key":"8576_CR55","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A et al (1987) MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol 149:351\u2013356. https:\/\/doi.org\/10.2214\/ajr.149.2.351","journal-title":"AJR Am J Roentgenol"},{"key":"8576_CR56","doi-asserted-by":"crossref","unstructured":"Charidimou A, Boulouis G, Pasi M, et al (2022) The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study","DOI":"10.1161\/str.52.suppl_1.36"},{"key":"8576_CR57","doi-asserted-by":"publisher","unstructured":"Zanon Zotin MC, Makkinejad N, Schneider JA et al (2024) Sensitivity and specificity of the Boston criteria version 2.0 for the diagnosis of cerebral amyloid angiopathy in a community-based sample. Neurology 102. https:\/\/doi.org\/10.1212\/WNL.0000000000207940","DOI":"10.1212\/WNL.0000000000207940"},{"key":"8576_CR58","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2015.4078","volume":"73","author":"E Auriel","year":"2016","unstructured":"Auriel E, Charidimou A, Edip Gurol M et al (2016) Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol 73:197\u2013202. https:\/\/doi.org\/10.1001\/jamaneurol.2015.4078","journal-title":"JAMA Neurol"},{"key":"8576_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, Dekosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:270\u2013279","journal-title":"Alzheimers Dement"},{"key":"8576_CR60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"key":"8576_CR61","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3174\/ajnr.A4248","volume":"36","author":"S Shams","year":"2015","unstructured":"Shams S, Martola J, Cavallin L et al (2015) SWI or T2\u2217: which MRI sequence to use in the detection of cerebral microbleeds? The Karolinska Imaging Dementia Study. Am J Neuroradiol 36:1089\u20131095. https:\/\/doi.org\/10.3174\/ajnr.A4248","journal-title":"Am J Neuroradiol"},{"key":"8576_CR62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21:66\u201377","journal-title":"Lancet Neurol"},{"key":"8576_CR63","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, O\u2019Bryant SE, Molinuevo JL et al (2018) Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 14:639\u2013652","journal-title":"Nat Rev Neurol"},{"key":"8576_CR64","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J (2023) Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging 3:506\u2013519. https:\/\/doi.org\/10.1038\/s43587-023-00403-3","journal-title":"Nat Aging"},{"key":"8576_CR65","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Fowler NR (2024) Alzheimer disease blood biomarkers: considerations for population-level use. Nat Rev Neurol 20:495\u2013504","journal-title":"Nat Rev Neurol"},{"key":"8576_CR66","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Tideman P, Mattsson-Carlgren N et al (2024) Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. https:\/\/doi.org\/10.1001\/jama.2024.13855","DOI":"10.1001\/jama.2024.13855"},{"key":"8576_CR67","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Warmenhoven N, Anastasi F et al (2025) Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03622-w","DOI":"10.1038\/s41591-025-03622-w"},{"key":"8576_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105805","volume":"117","author":"S Lehmann","year":"2025","unstructured":"Lehmann S, Gabelle A, Duchiron M et al (2025) Comparative performance of plasma pTau181\/A\u03b242, pTau217\/A\u03b242 ratios, and individual measurements in detecting brain amyloidosis. EBioMedicine 117:105805. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105805","journal-title":"EBioMedicine"},{"key":"8576_CR69","unstructured":"(2025) FDA Clears First Blood Test Used in Diagnosing Alzheimer\u2019s Disease. In: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease"},{"key":"8576_CR70","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL et al (2022) The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement 18:2669\u20132686","journal-title":"Alzheimers Dement"},{"key":"8576_CR71","doi-asserted-by":"publisher","unstructured":"Hazan J, Liu KY, Isaacs JD, Howard R (2025) Cut-points and gray zones: the challenges of integrating Alzheimer\u2019s disease plasma biomarkers into clinical practice. Alzheimers Dement 21. https:\/\/doi.org\/10.1002\/alz.70113","DOI":"10.1002\/alz.70113"},{"key":"8576_CR72","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S et al (2023) A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging 3:1079\u20131090. https:\/\/doi.org\/10.1038\/s43587-023-00471-5","journal-title":"Nat Aging"},{"key":"8576_CR73","doi-asserted-by":"publisher","unstructured":"Benussi A, Huber H, Tan K et al (2025) Plasma p-tau217 and neurofilament\/p-tau217 ratio in differentiating Alzheimer\u2019s disease from syndromes associated with frontotemporal lobar degeneration. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.14482","DOI":"10.1002\/alz.14482"},{"key":"8576_CR74","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Whitson HE, Allen LA et al (2025) Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimers Dement 21. https:\/\/doi.org\/10.1002\/alz.70535","DOI":"10.1002\/alz.70535"},{"key":"8576_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M (2019) Advantages and disadvantages of the use of the CSF amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther 11:1\u201315","journal-title":"Alzheimers Res Ther"},{"key":"8576_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70031","author":"M Brendel","year":"2024","unstructured":"Brendel M, Parvizi T, Gn\u00f6rich J et al (2024) A\u03b2 status assessment in a hypothetical scenario prior to treatment with disease-modifying therapies: evidence from 10-year real-world experience at university memory clinics. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. https:\/\/doi.org\/10.1002\/dad2.70031","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"8576_CR77","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s10072-021-05704-2","volume":"43","author":"M Nerattini","year":"2022","unstructured":"Nerattini M, Rubino F, Arnone A et al (2022) Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements. Neurol Sci 43:2469\u20132480. https:\/\/doi.org\/10.1007\/s10072-021-05704-2","journal-title":"Neurol Sci"},{"key":"8576_CR78","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jalz.2014.03.003","volume":"10","author":"JL Molinuevo","year":"2014","unstructured":"Molinuevo JL, Blennow K, Dubois B et al (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s biomarkers standardization initiative. Alzheimers Dement 10:808\u2013817","journal-title":"Alzheimers Dement"},{"key":"8576_CR79","doi-asserted-by":"publisher","unstructured":"Bailly M, Destrieux C, Hommet C et al (2015) Precuneus and cingulate cortex atrophy and hypometabolism in patients with Alzheimer\u2019s disease and mild cognitive impairment: MRI and 18F-FDG PET quantitative analysis using FreeSurfer. Biomed Res Int 2015. https:\/\/doi.org\/10.1155\/2015\/583931","DOI":"10.1155\/2015\/583931"},{"key":"8576_CR80","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/brain\/awac158","volume":"146","author":"EM Vromen","year":"2023","unstructured":"Vromen EM, de Boer SCM, Teunissen CE (2023) Biomarker A+T-: is this Alzheimer\u2019s disease or not? A combined CSF and pathology study. Brain 146:1166\u20131174. https:\/\/doi.org\/10.1093\/brain\/awac158","journal-title":"Brain"},{"key":"8576_CR81","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","volume":"14","author":"LM Shaw","year":"2018","unstructured":"Shaw LM, Arias J, Blennow K et al (2018) Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement 14:1505\u20131521","journal-title":"Alzheimers Dement"},{"key":"8576_CR82","doi-asserted-by":"publisher","unstructured":"Bertens D, Tijms BM, Scheltens P et al (2017) Unbiased estimates of cerebrospinal fluid \u03b2-amyloid 1-42 cutoffs in a large memory clinic population. Alzheimer's Res Ther 9. https:\/\/doi.org\/10.1186\/s13195-016-0233-7","DOI":"10.1186\/s13195-016-0233-7"},{"key":"8576_CR83","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.25071","volume":"82","author":"P Vemuri","year":"2017","unstructured":"Vemuri P, Lesnick TG, Przybelski SA (2017) Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann Neurol 82:706\u2013718. https:\/\/doi.org\/10.1002\/ana.25071","journal-title":"Ann Neurol"},{"key":"8576_CR84","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jalz.2011.10.003","volume":"8","author":"D Paternic\u00f2","year":"2012","unstructured":"Paternic\u00f2 D, Galluzzi S, Drago V et al (2012) Cerebrospinal fluid markers for Alzheimer\u2019s disease in a cognitively healthy cohort of young and old adults. Alzheimers Dement 8:520\u2013527. https:\/\/doi.org\/10.1016\/j.jalz.2011.10.003","journal-title":"Alzheimers Dement"},{"key":"8576_CR85","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/alz.12105","volume":"16","author":"Z Ismail","year":"2020","unstructured":"Ismail Z, Black SE, Camicioli R et al (2020) Recommendations of the 5th Canadian consensus conference on the diagnosis and treatment of dementia. Alzheimers Dement 16:1182\u20131195. https:\/\/doi.org\/10.1002\/alz.12105","journal-title":"Alzheimers Dement"},{"key":"8576_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-025-01547-3","author":"S Buscarnera","year":"2025","unstructured":"Buscarnera S, Canevelli M, Bruno G (2025) Unraveling the link between frailty and Alzheimer\u2019s disease biomarkers in patients with mild cognitive impairment. Geroscience. https:\/\/doi.org\/10.1007\/s11357-025-01547-3","journal-title":"Geroscience"},{"key":"8576_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12601","author":"WWT Aye","year":"2024","unstructured":"Aye WWT, Stark MR, Horne KL et al (2024) Early-phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson\u2019s disease. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. https:\/\/doi.org\/10.1002\/dad2.12601","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"8576_CR88","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264256","author":"C Boccalini","year":"2023","unstructured":"Boccalini C, Peretti DE, Ribaldi F (2023) Early-phase 18F-florbetapir and 18F-flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.122.264256","journal-title":"J Nucl Med"},{"key":"8576_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07063-4","author":"C Boccalini","year":"2025","unstructured":"Boccalini C, Peretti DE, Mathoux G et al (2025) Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer\u2019s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-024-07063-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8576_CR90","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251340380","author":"JA Lojo-Ram\u00edrez","year":"2025","unstructured":"Lojo-Ram\u00edrez JA, Fern\u00e1ndez-Rodr\u00edguez P, Guerra-G\u00f3mez M et al (2025) Evaluation of early-phase 18F-florbetaben PET as a surrogate biomarker of neurodegeneration: in-depth comparison with 18F-FDG PET at group and single patient level. J Alzheimers Dis. https:\/\/doi.org\/10.1177\/13872877251340380","journal-title":"J Alzheimers Dis"},{"key":"8576_CR91","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1192\/bjp.bp.114.160804","volume":"208","author":"MJ Firbank","year":"2016","unstructured":"Firbank MJ, Lloyd J, Williams D et al (2016) An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer\u2019s disease according to presence of medial temporal lobe atrophy. Br J Psychiatry 208:491\u2013496. https:\/\/doi.org\/10.1192\/bjp.bp.114.160804","journal-title":"Br J Psychiatry"},{"key":"8576_CR92","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1001\/jama.286.17.2120","volume":"286","author":"DH Silverman","year":"2001","unstructured":"Silverman DH, Small GW, Chang CY (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120\u20132127. https:\/\/doi.org\/10.1001\/jama.286.17.2120","journal-title":"JAMA"},{"key":"8576_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S et al (2022) Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/s13195-022-01124-2","journal-title":"Alzheimers Res Ther"},{"key":"8576_CR94","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC et al (2022) Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol 79:1250\u20131259. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392","journal-title":"JAMA Neurol"},{"issue":"1","key":"8576_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC et al (2015) The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11(1):1-15.e4. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003","journal-title":"Alzheimers Dement"},{"key":"8576_CR96","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1007\/s00259-017-3750-0","volume":"44","author":"D Cecchin","year":"2017","unstructured":"Cecchin D, Barthel H, Poggiali D et al (2017) A new integrated dual time-point amyloid PET\/MRI data analysis method. Eur J Nucl Med Mol Imaging 44:2060\u20132072. https:\/\/doi.org\/10.1007\/s00259-017-3750-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8576_CR97","doi-asserted-by":"publisher","unstructured":"Collij LE, Bischof GN, Altomare D et al (2024) Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.124.268119","DOI":"10.2967\/jnumed.124.268119"},{"key":"8576_CR98","doi-asserted-by":"publisher","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA et al (2020) Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimer's Res Ther 12. https:\/\/doi.org\/10.1186\/s13195-020-00587-5","DOI":"10.1186\/s13195-020-00587-5"},{"key":"8576_CR99","doi-asserted-by":"publisher","unstructured":"Corriveau-Lecavalier N, Botha H, Graff-Radford J et al (2024) Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome. Brain Commun 6. https:\/\/doi.org\/10.1093\/braincomms\/fcae183","DOI":"10.1093\/braincomms\/fcae183"},{"key":"8576_CR100","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006\u20131014","journal-title":"Neurology"},{"key":"8576_CR101","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","volume":"13","author":"SJ Crutch","year":"2017","unstructured":"Crutch SJ, Schott JM, Rabinovici GD et al (2017) Consensus classification of posterior cortical atrophy. Alzheimers Dement 13:870\u2013884. https:\/\/doi.org\/10.1016\/j.jalz.2017.01.014","journal-title":"Alzheimers Dement"},{"key":"8576_CR102","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.25333","volume":"84","author":"D Bergeron","year":"2018","unstructured":"Bergeron D, Gorno-Tempini ML, Rabinovici GD (2018) Prevalence of amyloid-\u03b2 pathology in distinct variants of primary progressive aphasia. Ann Neurol 84:729\u2013740","journal-title":"Ann Neurol"},{"key":"8576_CR103","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S1474-4422(23)00414-3","volume":"23","author":"M Chapleau","year":"2024","unstructured":"Chapleau M, La Joie R, Yong K (2024) Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. Lancet Neurol 23:168\u2013177. https:\/\/doi.org\/10.1016\/S1474-4422(23)00414-3","journal-title":"Lancet Neurol"},{"key":"8576_CR104","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1093\/brain\/awv191","volume":"138","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Pijnenburg YAL, Perry DC et al (2015) The behavioural\/dysexecutive variant of Alzheimer\u2019s disease: clinical, neuroimaging and pathological features. Brain 138:2732\u20132749. https:\/\/doi.org\/10.1093\/brain\/awv191","journal-title":"Brain"},{"key":"8576_CR105","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1007\/s00415-015-7904-3","volume":"262","author":"RW Paterson","year":"2015","unstructured":"Paterson RW, Toombs J, Slattery CF (2015) Dissecting IWG-2 typical and atypical Alzheimer\u2019s disease: insights from cerebrospinal fluid analysis. J Neurol 262:2722\u20132730","journal-title":"J Neurol"},{"key":"8576_CR106","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.neurobiolaging.2015.04.011","volume":"36","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Mattsson N, Teunissen CE (2015) Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer\u2019s disease. Neurobiol Aging 36:2340\u20132347","journal-title":"Neurobiol Aging"},{"key":"8576_CR107","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina S, La Joie R, Petersen C et al (2021) Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain 144:2186\u20132198. https:\/\/doi.org\/10.1093\/brain\/awab099","journal-title":"Brain"},{"key":"8576_CR108","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP et al (2021) Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med 27:871\u2013881. https:\/\/doi.org\/10.1038\/s41591-021-01309-6","journal-title":"Nat Med"},{"key":"8576_CR109","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1212\/WNL.0000000000007967","volume":"93","author":"Y Qiu","year":"2019","unstructured":"Qiu Y, Jacobs DM, Messer K (2019) Cognitive heterogeneity in probable Alzheimer disease: clinical and neuropathologic features. Neurology 93:e778\u2013e790. https:\/\/doi.org\/10.1212\/WNL.0000000000007967","journal-title":"Neurology"},{"key":"8576_CR110","doi-asserted-by":"publisher","unstructured":"Jicha GA, Abner EL, Coskun EP et al (2024) Perspectives on the clinical use of anti-amyloid therapy for the treatment of Alzheimer\u2019s disease: insights from the fields of cancer, rheumatology, and neurology. Alzheimer\u2019s Dement Transl Res Clin Interv 10. https:\/\/doi.org\/10.1002\/trc2.12500","DOI":"10.1002\/trc2.12500"},{"key":"8576_CR111","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/alz.12231","volume":"17","author":"V Planche","year":"2021","unstructured":"Planche V, Bouteloup V, Mangin JF et al (2021) Clinical relevance of brain atrophy subtypes categorization in memory clinics. Alzheimers Dement 17:641\u2013652. https:\/\/doi.org\/10.1002\/alz.12231","journal-title":"Alzheimers Dement"},{"key":"8576_CR112","doi-asserted-by":"publisher","unstructured":"Kapasi A, James BD, Yu L et al (2025) Mixed pathologies and cognitive outcomes in persons considered for anti-amyloid treatment eligibility assessment. Neurology 105. https:\/\/doi.org\/10.1212\/WNL.0000000000214004","DOI":"10.1212\/WNL.0000000000214004"},{"key":"8576_CR113","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496\u2013503","journal-title":"Neurology"},{"key":"8576_CR114","doi-asserted-by":"publisher","unstructured":"Townley RA, Graff-Radford J, Mantyh WG et al (2020) Progressive dysexecutive syndrome due to Alzheimer\u2019s disease: a description of 55 cases and comparison to other phenotypes. Brain Commun 2. https:\/\/doi.org\/10.1093\/braincomms\/fcaa068","DOI":"10.1093\/braincomms\/fcaa068"},{"key":"8576_CR115","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/wnl.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren N, Grinberg LT, Boxer A et al (2022) Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 98:e1137\u2013e1150. https:\/\/doi.org\/10.1212\/wnl.0000000000200040","journal-title":"Neurology"},{"key":"8576_CR116","doi-asserted-by":"publisher","unstructured":"Ghirelli A, Tosakulwong N, Weigand SD et al (2020) Sensitivity\u2013specificity of tau and amyloid \u03b2 positron emission tomography in frontotemporal lobar degeneration. Ann Neurol:1009\u20131022. https:\/\/doi.org\/10.1002\/ana.25893","DOI":"10.1002\/ana.25893"},{"key":"8576_CR117","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1093\/brain\/awx254","volume":"140","author":"DC Perry","year":"2017","unstructured":"Perry DC, Brown JA, Possin KL (2017) Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain 140:3329\u20133345. https:\/\/doi.org\/10.1093\/brain\/awx254","journal-title":"Brain"},{"key":"8576_CR118","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jnnp-2021-328586","volume":"93","author":"S Koga","year":"2022","unstructured":"Koga S, Josephs KA, Aiba I (2022) Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry 93:919\u2013929","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8576_CR119","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1212\/WNL.0000000000008818","volume":"94","author":"K Kantarci","year":"2020","unstructured":"Kantarci K, Lowe VJ, Chen Q et al (2020) \u03b2-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology 94:e282\u2013e291. https:\/\/doi.org\/10.1212\/WNL.0000000000008818","journal-title":"Neurology"},{"key":"8576_CR120","doi-asserted-by":"publisher","unstructured":"Bregman N, Nathan T, Shir D et al (2025) Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease. Alzheimer's Res Ther 17. https:\/\/doi.org\/10.1186\/s13195-025-01763-1","DOI":"10.1186\/s13195-025-01763-1"},{"key":"8576_CR121","doi-asserted-by":"publisher","unstructured":"Paczynski M, Hofmann A, Posey Z et al (2025) Lecanemab treatment in a specialty memory clinic. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1232","DOI":"10.1001\/jamaneurol.2025.1232"},{"key":"8576_CR122","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D (2024) APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med 30:1284\u20131291. https:\/\/doi.org\/10.1038\/s41591-024-02931-w","journal-title":"Nat Med"},{"key":"8576_CR123","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261:921\u2013923","journal-title":"Science"},{"key":"8576_CR124","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, Saunders AM, Schmechel D et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977\u20131981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8576_CR125","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1038\/s41380-020-0764-y","volume":"26","author":"H Stocker","year":"2021","unstructured":"Stocker H, Perna L, Weigl K et al (2021) Prediction of clinical diagnosis of Alzheimer\u2019s disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years. Mol Psychiatry 26:5812\u20135822. https:\/\/doi.org\/10.1038\/s41380-020-0764-y","journal-title":"Mol Psychiatry"},{"key":"8576_CR126","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jalz.2011.12.004","volume":"9","author":"MM Corrada","year":"2013","unstructured":"Corrada MM, Paganini-Hill A, Berlau DJ, Kawas CH (2013) Apolipoprotein e genotype, dementia, and mortality in the oldest old: the 90+ study. Alzheimers Dement 9:12\u201318. https:\/\/doi.org\/10.1016\/j.jalz.2011.12.004","journal-title":"Alzheimers Dement"},{"key":"8576_CR127","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/GIM.0b013e31821d69b8","volume":"13","author":"JS Goldman","year":"2011","unstructured":"Goldman JS, Hahn SE, Catania JW et al (2011) Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 13:597\u2013605. https:\/\/doi.org\/10.1097\/GIM.0b013e31821d69b8","journal-title":"Genet Med"},{"key":"8576_CR128","doi-asserted-by":"crossref","unstructured":"Farrer L (1995) Statement on use of apolipoprotein E testing for Alzheimer disease recent advances in the genetics of Alzheimer disease (AD) have raised the possibility of widespread DNA test-From the Academy of Neurology, the American Psychiatric Association, and the National In-stitutes of Health\\p=m-\\Department of Education Working Group on Ethical, Legal, and Social Implications of","DOI":"10.1001\/jama.1995.03530200063039"},{"key":"8576_CR129","doi-asserted-by":"publisher","unstructured":"Yamazaki Y, Zhao N, Caulfield TR et al (2019) Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15. https:\/\/doi.org\/10.1038\/s41582-019-0228-7","DOI":"10.1038\/s41582-019-0228-7"},{"key":"8576_CR130","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/bcpt.14055","volume":"135","author":"J Poblano","year":"2024","unstructured":"Poblano J, Castillo-Tob\u00edas I, Berlanga L et al (2024) Drugs targeting APOE4 that regulate beta-amyloid aggregation in the brain: therapeutic potential for Alzheimer\u2019s disease. Basic Clin Pharmacol Toxicol 135:237\u2013249","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"8576_CR131","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40263-024-01097-w","volume":"38","author":"MH Rosenbloom","year":"2024","unstructured":"Rosenbloom MH, O\u2019Donohue T, Zhou-Clark D et al (2024) A framework for the administration of anti-amyloid monoclonal antibody treatments in early-stage Alzheimer\u2019s disease. CNS Drugs 38:493\u2013505. https:\/\/doi.org\/10.1007\/s40263-024-01097-w","journal-title":"CNS Drugs"},{"key":"8576_CR132","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","volume":"101","author":"VK Ramanan","year":"2023","unstructured":"Ramanan VK, Armstrong MJ, Choudhury P et al (2023) Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology. Neurology 101:842\u2013852. https:\/\/doi.org\/10.1212\/WNL.0000000000207757","journal-title":"Neurology"},{"key":"8576_CR133","unstructured":"Kane M (2024) Lecanemab therapy and APOE genotype"},{"key":"8576_CR134","doi-asserted-by":"crossref","unstructured":"Greenberg BD, Lemere CA, Barnes LL et al (2023) Prescribing anti-amyloid immunotherapies to treat Alzheimer\u2019s disease: fully informing patient decisions. Alzheimer\u2019s Dement Transl Res Clin Interv 9","DOI":"10.1002\/trc2.12426"},{"key":"8576_CR135","unstructured":"European Medicine Agency (2025) Leqembi: EPAR - product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/leqembi-epar-product-information_en.pdf. Accessed 23 Aug 2025"},{"key":"8576_CR136","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s00415-023-11642-0","volume":"270","author":"M Filippi","year":"2023","unstructured":"Filippi M, Cecchetti G, Cagnin A et al (2023) Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer\u2019s disease: an expert opinion and practical guideline. J Neurol 270:3159\u20133170. https:\/\/doi.org\/10.1007\/s00415-023-11642-0","journal-title":"J Neurol"},{"key":"8576_CR137","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/13872877251331243","volume":"105","author":"D Urso","year":"2025","unstructured":"Urso D, Introna A, Gnoni V et al (2025) Donanemab eligibility in early Alzheimer\u2019s disease: a real-world study. J Alzheimers Dis 105:745\u2013750. https:\/\/doi.org\/10.1177\/13872877251331243","journal-title":"J Alzheimers Dis"},{"key":"8576_CR138","doi-asserted-by":"publisher","unstructured":"Logroscino G, Urso D, Gnoni V et al (2025) Mild cognitive impairment and early Alzheimer\u2019s disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: a simultaneous real-word study on aducanumab and lecanemab. Eur J Neurol 32. https:\/\/doi.org\/10.1111\/ene.16534","DOI":"10.1111\/ene.16534"},{"key":"8576_CR139","doi-asserted-by":"publisher","unstructured":"Padovani A, Caratozzolo S, Rozzini L et al (2021) \u201cReal-world\u201d eligibility for aducanumab depends on clinical setting and patients\u2019 journey. J Am Geriatr Soc:8\u201310. https:\/\/doi.org\/10.1111\/jgs.17530","DOI":"10.1111\/jgs.17530"},{"key":"8576_CR140","doi-asserted-by":"publisher","first-page":"392","DOI":"10.7416\/ai.2024.2602","volume":"36","author":"ZD Valle","year":"2024","unstructured":"Valle ZD, Signorelli C, Renzi C (2024) Primary care doctors retirements in the context of an ageing population in Italy. Ann Ig 36:392\u2013404. https:\/\/doi.org\/10.7416\/ai.2024.2602","journal-title":"Ann Ig"},{"key":"8576_CR141","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JAD-240594","volume":"101","author":"F Giaquinto","year":"2024","unstructured":"Giaquinto F, Lorenzini P, Salvi E et al (2024) The profile of the Italian centers for cognitive disorders and dementia in the context of new drugs in Alzheimer\u2019s disease. J Alzheimers Dis 101:509\u2013524. https:\/\/doi.org\/10.3233\/JAD-240594","journal-title":"J Alzheimers Dis"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08576-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:41:19Z","timestamp":1764895279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08576-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":141,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["8576"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08576-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This position paper does not require formal Health Ethical Approval as it does not report data collected on patients or humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}},{"value":"This position paper did not receive any dedicated grant from public agencies, commercial enterprises, or not-for-profit organisations. The meeting of the expert panel on Alzheimer (EPA) held in Florence on 24 January 2025 was organised and fully financed with internal funds of the Italian Society of Neurology (SIN) together with the collaborating scientific societies listed in the manuscript. No industry sponsorship was involved in the planning, drafting, or decision to submit the present work. Alba Rosa Alfano reports no relevant conflicts of interest. Federica Agosta is Associate Editor of NeuroImage: Clinical and has received speaker honoraria from Biogen Idec, Eli Lilly, Roche, Zambon, and Italfarmaco, and editing fees from Elsevier; she received research support from the Italian Ministry of Health, the Italian Ministry of University & Research, AriSLA, the European Research Council, and the Foundation for Alzheimer\u2019s Research. Antonio Antico reports no conflicts of interest. Alberto Benussi has received speaker honoraria from Eli Lilly and Angelini Pharma; he received research grants from Airalzh, Fondazione Cariplo, the Fondation pour la Recherche sur Alzheimer, and the Italian Ministry of University & Research; he is listed as an inventor on issued patents on the use of non-invasive brain stimulation for the differential diagnosis of dementia and to increase cognitive functions in patients with neurodegenerative disorders. Giuseppe Bellelli has received research funding from the Italian Ministry of Health and University, and has received speaker honoraria from Eli Lilly, PIAM, GSK, Italfarmaco, Nestl\u00e9 and Damor. Gabriella Bottini reports no conflicts of interest. Marco Bozzali reports no conflicts of interest. Ovidio Brignoli reports no conflicts of interest. Giuseppe Bruno reports no conflicts of interest; he received financial compensation from Eli Lilly for participation on the GERAS advisory board. Annachiara Cagnin has received consulting fees and\/or speaker honoraria from Eli Lilly, Biogen, Eisai, Roche, PIAM, Novonordisk and Lundbeck, and research support from the Italian Ministry of Health and Regione Veneto. Sonia Francesca Calloni reports no conflicts of interest. Diego Cecchin reports no conflicts of interest. Marcello Ciaccio reports no conflicts of interest. Sirio Cocozza has served on an Amicus Therapeutics advisory board, has received speaker fees from Sanofi and Amicus Therapeutics, and research funding from the Fondazione Italiana Sclerosi Multipla. Mirco Cosottini has received a speaker honorarium from GE Healthcare, Ely Lilli, Roche. Diego De Leo has received consulting fees and\/or speaker honoraria from Lundbeck, Neopharmed, and PIAM. Andrea Falini reports no conflicts of interest. Lorenzo Gaetani has received honoraria, travel grants, or advisory board fees from Almirall, Biogen, Euroimmun, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, Teva, Fujirebio, and Eli Lilly. Fabio Gotta reports no conflicts of interest. Maria Infantino reports no conflicts of interest. Raffaele Lodi reports no conflicts of interest. Giancarlo Logroscino has served as investigator for clinical trials sponsored by Biogen Pharmaceuticals, Axovant, Alector, Denali, Roche, Eisai, Genentech, Amylyx, PIAM Farmaceutici SpA; he has served as a consultant and has given Lectures for EISAI, Roche, Lilly, Piam Farmaceutici Spa, Biogen. Elena Marcello has received speaker honoraria from Eli Lilly and GE Healthcare, advisory board fees from Roche, teaching fees from Eisai; she has received research grants from the Italian Ministry of Research and University, Giovanni Armenise Harvard Foundation, AIRALZH ONLUS, the Italian Ministry of Enterprises and Made in Italy, Alzheimer Association, Bright Focus Foundation. Camillo Marra has received research support from Novo Nordisk and speaker honoraria from Biogen, Roche, Novo Nordisk, PIAM, and Angelini.Walter Marrocco reports no conflicts of interest. Patrizia Mecocci has received grants\/contracts from HORIZON-JU-RIA Program AD-Riddle and Horizon 2020 Lethe, honoraria from PIAM, Angelini, and Epitech, and served on the advisory board of Primus. Enrico Mossello has been principal investigator in Novo Nordisk, Avanir and Eli Lilly trials and has received speaker honoraria from Eli Lilly, Johnson and Johnson, and Neuraxpharm. Alessandro Padovani is a consultant and scientific advisory board member for GE Healthcare, Eli Lilly, and Actelion; he has received speaker honoraria from Nutricia, PIAM, Langstone Technology, GE Healthcare, Lilly, UCB Pharma, and Chiesi, and research funding from Nutricia, Roche, GE Healthcare, Eli Lilly, Biogen, Pfizer, Lundbeck, the Italian Ministry of Health, and IMI H2020 initiatives. Lorenzo Palleschi reports no conflicts of interest. Leonardo Pantoni is member of the editorial board of Neurology, Cerebrovascular Diseases, European Stroke Journal, Cerebral Circulation Cognition and Behavior, and associate editor of Neurological Sciences; he has received consultancy fees from Medtronic, PIAM and Amicus. Lucilla Parnetti serves on advisory boards for Fujirebio, IBL, Roche, and Merck and holds collaboration contracts with ADx Neurosciences, Amprion Inc., and Fujirebio. Sandro Sorbi reports no conflicts of interest. Alessandro Tessitore has served as associate editor for European Journal of Neurology, serves on advisory boards for Zambon, Eli Lilly and received speaker honoraria from Lundbeck, AbbVie, Bial, Eli Lilly, TEVA, Zambon, UCB Pharma, and Chiesi, and research funding from the Italian Ministry of Health, and Italian Ministry of University & Research. Andrea Ungar reports no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}